WO2004039961A3 - Trefoil domain-containing polypeptides and uses thereof - Google Patents

Trefoil domain-containing polypeptides and uses thereof Download PDF

Info

Publication number
WO2004039961A3
WO2004039961A3 PCT/US2003/034796 US0334796W WO2004039961A3 WO 2004039961 A3 WO2004039961 A3 WO 2004039961A3 US 0334796 W US0334796 W US 0334796W WO 2004039961 A3 WO2004039961 A3 WO 2004039961A3
Authority
WO
WIPO (PCT)
Prior art keywords
containing polypeptides
trefoil domain
trefoil
peptide fragments
domain
Prior art date
Application number
PCT/US2003/034796
Other languages
French (fr)
Other versions
WO2004039961A2 (en
Inventor
Nicholas P Barker
Daniel K Podolsky
Original Assignee
Gi Company Inc
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/305,747 external-priority patent/US20030114384A1/en
Priority claimed from US10/397,953 external-priority patent/US20030186880A1/en
Priority claimed from US10/431,805 external-priority patent/US20030185838A1/en
Priority claimed from US10/434,607 external-priority patent/US20030186882A1/en
Priority claimed from US10/434,636 external-priority patent/US20030185839A1/en
Priority claimed from US10/435,406 external-priority patent/US20030181384A1/en
Priority claimed from US10/434,752 external-priority patent/US7538082B2/en
Priority to AU2003286844A priority Critical patent/AU2003286844A1/en
Priority to JP2005501919A priority patent/JP2006516964A/en
Priority to EP03778060A priority patent/EP1581623A2/en
Application filed by Gi Company Inc, Gen Hospital Corp filed Critical Gi Company Inc
Publication of WO2004039961A2 publication Critical patent/WO2004039961A2/en
Publication of WO2004039961A3 publication Critical patent/WO2004039961A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention features compositions and methods for treating and preventing epithelial lesions and disorders by administering trefoil domain-containing polypeptides and trefoil peptide fragments. The trefoil domain-containing polypeptides and trefoil peptide fragments can be administered alone or in combination with other therapeutic agents.
PCT/US2003/034796 2002-10-31 2003-10-31 Trefoil domain-containing polypeptides and uses thereof WO2004039961A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03778060A EP1581623A2 (en) 2002-10-31 2003-10-31 Trefoil domain-containing polypeptides and uses thereof
JP2005501919A JP2006516964A (en) 2002-10-31 2003-10-31 Trefoil type domain-containing polypeptide and use thereof
AU2003286844A AU2003286844A1 (en) 2002-10-31 2003-10-31 Trefoil domain-containing polypeptides and uses thereof

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US42270802P 2002-10-31 2002-10-31
US60/422,708 2002-10-31
US10/305,747 2002-11-27
US10/305,747 US20030114384A1 (en) 2001-11-28 2002-11-27 Methods and compositions for treating lesions of the respiratory epithelium
US10/397,953 2003-03-26
US10/397,953 US20030186880A1 (en) 2002-03-26 2003-03-26 Combination therapy using trefoil peptides
US10/431,805 US20030185838A1 (en) 2001-11-28 2003-05-08 Methods and compositions for treating lesions of the respiratory epithelium
US10/431,805 2003-05-08
US10/434,607 US20030186882A1 (en) 2001-07-31 2003-05-09 Methods and compositions for treating and preventing distal bowel lesions
US10/434,636 US20030185839A1 (en) 2001-10-05 2003-05-09 Methods and compositions for treating dermal lesions
US10/435,406 US20030181384A1 (en) 2001-09-06 2003-05-09 Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US10/435,406 2003-05-09
US10/434,752 US7538082B2 (en) 2001-04-24 2003-05-09 Methods and compositions for treating oral and esophageal lesions
US10/434,636 2003-05-09
US10/434,607 2003-05-09
US10/434,752 2003-05-09

Publications (2)

Publication Number Publication Date
WO2004039961A2 WO2004039961A2 (en) 2004-05-13
WO2004039961A3 true WO2004039961A3 (en) 2007-11-15

Family

ID=32234546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034796 WO2004039961A2 (en) 2002-10-31 2003-10-31 Trefoil domain-containing polypeptides and uses thereof

Country Status (4)

Country Link
EP (1) EP1581623A2 (en)
JP (1) JP2006516964A (en)
AU (1) AU2003286844A1 (en)
WO (1) WO2004039961A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK10892A (en) * 1992-01-29 1993-09-12 Brix Hansen Helge VACUUM trigger
EP1833991A4 (en) * 2004-12-22 2011-11-16 Auckland Uniservices Ltd Trefoil factors and methods of treating proliferation disorders using same
EP2575864A1 (en) * 2010-06-04 2013-04-10 Trifoilium ApS Trefoil factors (tff) for the treatment of chronic pulmonary diseases
CN107375939B (en) * 2017-07-19 2021-02-23 中国药科大学 Amphotericin B polypeptide hydrogel drug-loading system for treating fungal infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541210A (en) * 1993-12-17 1996-07-30 The Procter & Gamble Company 5-(2-imidazolinylamino)benzimidazole compounds useful as alpha-2 andrenoceptor agonists
WO1997038712A1 (en) * 1996-04-12 1997-10-23 The General Hospital Corporation Intestinal trefoil proteins
US5783416A (en) * 1993-01-21 1998-07-21 Novo Nordisk A/S Human spasmolytic polypeptide in glycosylated form

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1739178T3 (en) * 1999-07-05 2010-11-22 Actogenix Nv Delivery of threefold peptides
WO2002046226A2 (en) * 2000-12-08 2002-06-13 Novo Nordisk A/S Trefoil factor 2 (tff2) peptides with moiety attached to asn15
MXPA03009772A (en) * 2001-04-24 2004-02-23 Gen Hospital Corp Methods and compositions for treating oral and eosophageal lesions.
WO2003082196A2 (en) * 2002-03-26 2003-10-09 The General Hospital Corporation Combination therapy using trefoil peptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221840B1 (en) * 1991-02-14 2001-04-24 The General Hospital Corporation Intestinal trefoil proteins
US5783416A (en) * 1993-01-21 1998-07-21 Novo Nordisk A/S Human spasmolytic polypeptide in glycosylated form
US5541210A (en) * 1993-12-17 1996-07-30 The Procter & Gamble Company 5-(2-imidazolinylamino)benzimidazole compounds useful as alpha-2 andrenoceptor agonists
WO1997038712A1 (en) * 1996-04-12 1997-10-23 The General Hospital Corporation Intestinal trefoil proteins

Also Published As

Publication number Publication date
JP2006516964A (en) 2006-07-13
AU2003286844A1 (en) 2004-05-25
EP1581623A2 (en) 2005-10-05
AU2003286844A8 (en) 2004-05-25
WO2004039961A2 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
SG149059A1 (en) Gastrointestinal proliferative factor and uses thereof
WO2003045332A3 (en) Methods and compositions for treating lesions of the respiratory epithelium
WO2008133928A3 (en) Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
ZA200500882B (en) Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis of treatment or liver disorders and epithelial cancer
WO2007101224A3 (en) Inhibitors of the unfolded protein response and methods for their use
WO2003082196A3 (en) Combination therapy using trefoil peptides
WO2006060680A3 (en) Mda-7 protein variants having antiproliferative activity
MXPA03009772A (en) Methods and compositions for treating oral and eosophageal lesions.
WO2002004421A3 (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2007123848A3 (en) Therapeutic compositions containing modified class i slrp proteins
AU2003229284A1 (en) Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
WO2003022205A3 (en) Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
WO2005123113A3 (en) Interferon compositions and methods of use thereof
WO2004039961A3 (en) Trefoil domain-containing polypeptides and uses thereof
WO2006029487A8 (en) Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
WO2006103354A3 (en) Dermatological and/or cosmetic composition containing proteins of the sirt family
AU2003221096A1 (en) Peptides, medicinal compositions containing the peptide and medicinal compositions for treating cancer
WO2002066492A3 (en) Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof
WO2004041296A3 (en) Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
WO2007126887A3 (en) Immunogenic compositions comprising polynucleotides encoding matrix protein 2 and methods of use
WO2000061171A3 (en) Uses of mammalian ox2 protein and related reagents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005501919

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003778060

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003778060

Country of ref document: EP